Angiotensin AT2 receptor-induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology.

Reza KhorooshiEmil Ulrikkaholm Tofte-HansenCamilla TygesenRoser Montanana-RosellHannah Liska LimburgJoanna MarczynskaNasrin AsgariUlrike Muscha SteckelingsTrevor Owens

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

Our findings identify AT2R as a novel potential therapeutic target for the treatment of NMOSD. Interleukin-10 signaling is an essential part of the protective mechanism counteracting NMOSD pathology.

Keyphrases

spectrum disorder
high glucose
angiotensin ii
drug induced
endothelial cells
climate change
binding protein
smoking cessation